GL1X · GenesisL1 explorer

MolNFT v1 · #91322 · protein

Human P38 alpha MAPK in complex with a novel and selective small molecule inhibitor

4F9Y · Mitogen-activated protein kinase 14: “Human P38 alpha MAPK in complex with a novel and selective small molecule inhibitor”. X-ray diffraction, 2 ligands (GG5, LM3), 5 pockets (best druggability 0.68). MolNFT v1 #91322 on GenesisL1…

PDB
4F9Y
Type
protein
Length
339 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Mitogen-activated protein kinase 14
EC
2.7.11.24
UniProt
Q16539
Ligands
GG5, LM3
Pockets
5 · best druggability 0.68

Structure

x-ray diffraction · 1 distinct chain · 41% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMitogen-activated protein kinase 14 (EC 2.7.11.24)protein33941% helix, 16% strandQ16539

Ligands and binding sites

  • GG5 · 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine · ligand · 2 copies · chains A
  • LM3 · N,N-dimethyl-6-(naphthalen-1-yl)-5-(pyridin-4-yl)pyridazin-3-amine · ligand · chains A
  • BME · Beta-mercaptoethanol · additive · 2 copies · chains A
  • PEG · Di(hydroxyethyl)ether · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14010.680.8039LM3, PEG
21260.650.8720GG5
31610.460.7632empty
4990.350.7317empty
5680.320.7415empty

Modifications

Observed in the structure: 2 covalent (additive adduct).

Compared structures

  • 4F9Y · Human P38 alpha MAPK In Complex With a Novel and Selective Small Molecule Inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.